Disappointment over corporate earnings weighed the markets down to a lower close with the Dow dropping 64 points to 16,417. Nasdaq added 3 points to 4218.
On the upside
Prosena Holding (Nasdaq: RNA) reported encouraging initial findings from the clinical development program of drisapersen to treat Duchenne Muscular Dystrophy.
Questcor Pharmaceuticals (Nasdaq: QCOR) reported encouraging prescription trends for Acthar.
A Seeking Alpha contributor highlighted recent positive business developments for Galena Biopharma (Nasdaq: GALE).
On the downside
Shares of American Capital Senior Floating (Nasdaq: ACSF) tumbled in its market debut.
An investigation by Chinese authorities into pyramid scheme allegations against Nu Skin Enterprises (NYSE: NUS) weighed down shares of rival Herbalife (NYSE: HLF).
Credit Suisse analyst Edward Kelly downgraded Kroger (NYSE: KR) from an Outperform rating to a Neutral rating and cut his price target from $48 to $39.
In the broad market, advancing issues outpaced decliners by a margin of more than 4 to 3 on the NYSE and by a nearly 9 to 7 on Nasdaq. The broader S&P 500 slipped 2 points to 1845. Bitcoin lost $10.27 or 1.11% to $928.92.
